Tests the CONDA stent retriever to remove clots in acute stroke

Trial details

Who runs it

Anaconda Biomed S.L.

Trial code

NCT07174505

Record updated

16 September 2025

Original description

The goal of this study is to evaluate the safety and performance of the CONDA stent retriever in patients with acute ischemic stroke due to large vessel occlusion, treated within 24 hours of symptom onset.Read full original descriptionShow less

A Prospective, Single-Arm, Multi-Center Study to Assess the Safety, Performance, and Preliminary Efficacy of Mechanical Thrombectomy Using the CONDA Stent Retriever in Subjects With Acute Ischemic Stroke

The goal of this study is to evaluate the safety and performance of the CONDA stent retriever in patients with acute ischemic stroke due to large vessel occlusion, treated within 24 hours of symptom onset.

The main objectives are:

* To determine the rate of device success, defined as the ability of the CONDA retriever to reach the blocked vessel, be deployed and retrieved successfully, and facilitate reperfusion. * To evaluate safety, measured as the rate of symptomatic intracranial hemorrhage within 24 hours of the procedure.

The use of CONDA in this study follows the same approach as other CE-marked stent retrievers. Supportive devices (such as long sheaths, guide catheters, balloon catheters, distal access catheters, the ANA funnel catheter, microcatheters, and microwires) may be used according to investigator preference and local practice, in line with their labeling and instructions for use.

Participants will:

* Be evaluated using standard clinical and imaging assessments to confirm eligibility. * Undergo mechanical thrombectomy with the CONDA device, with or without supportive devices as selected by the treating physician. * Have standard follow-up evaluations to assess treatment safety and effectiveness.

Inclusion: Age 18 to 85 years; Informed consent was obtained from subject or acceptable subject surrogate (e.g., next of kin, or legal representative); New focal disabling neurologic deficit consistent with acute cerebral ischemia; Baseline NIHSS obtained prior to procedure ≥ 6 points and ≤ 25 points; Pre-ictal mRS score of 0, 1 or 2; Treatable within 24 hours of stroke symptom onset; If indicated, thrombolytic therapy shall be initiated following recommendations established by the AHA/ASA and/or ESO Guidelines. Subjects eligible for IV thrombolysis should receive it without delay; Extended Thrombolysis in Cerebral Infarction (eTICI) Score 0 - 1, confirmed by angiography or CTA/MRA of the:; Intracranial internal carotid artery (ICA); Middle cerebral artery - M1 segment; Middle cerebral artery - M2 proximal or dominant segments; Imaging criteria:; Alberta Stroke Program Early CT Score (ASPECTS) 6 to 10 on baseline CT or DWI-MRI; If automated assessment, core volume of ≤50 cc on CTP/ DWI-MRI.

Exclusion: Rapid neurological improvement prior to enrollment suggesting resolution of stroke; Subject is participating in a concurrent study involving an investigational drug or device that would impact the primary endpoint of this study; eTICI score improvement to greater than eTICI 1 after initial screening and prior to intervention; Initially treated with a different thrombectomy device during the current study procedure; Subject was diagnosed with a stroke in the last 6 months; Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories; Clinical presentation suggests subarachnoid hemorrhage; Severe, sustained uncontrolled hypertension refractory to treatment (systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg); Serious, advanced, or terminal disease with anticipated life expectancy of less than 1 year; Known history of severe sensitivity (more than rash) to contrast medium; Known history of severe sensitivity to nickel, titanium metals or their alloys; Subject is a current user or has a recent history of cocaine and/or heroin use; CT or MRI evidence of hemorrhage (the presence of microbleeds is allowed); History of preexisting stent proximal to or at the occlusion site that may preclude safe deployment or recovery of the stent retriever; The following exclusion criteria will be assessed intra-operatively:; Underlying intracranial atherosclerotic disease (ICAD) lesions responsible for the target occlusion; Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with antivitamin K, with INR >3.0; Known baseline glucose of <50 mg/dL or >400 mg/dL; Known renal insufficiency with creatinine ≥3 mg/dL or glomerular filtration rate (GFR) <30 mL/min; The following exclusion criteria will be assessed pre-operatively:; Subject requires hemodialysis or peritoneal dialysis; Known pregnancy and/or lactating female; Subject is unlikely to be available for a 90-day follow-up (e.g., no fixed home address, visitor from overseas, etc.); CT or MRI evidence of significant mass effect with midline shift; CT or MRI evidence of intracranial tumor (except asymptomatic meningioma of ≤ 2cm in diameter); CT or MR evidence of cerebral vasculitis; Suspicion of aortic dissection, presumed septic embolus, or bacterial endocarditis; Vessel tortuosity too difficult to allow endovascular access of the intracranial internal carotid artery (ICA) per investigator judgement. Indicators of vessel tortuosity include but are not limited to the presence of carotid loops and type 3 aortic arches; Evidence of tandem lesions, including complete occlusion, high-grade stenosis or arterial dissection in the extracranial or intracranial internal carotid artery (ICA), requiring treatment or preventing access to thrombus; Occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation); Inability to gain arterial access.

ClinicalTrials.gov NCT07174505